Pneumologie. Traitement de la fibrose pulmonaire idiopathique: un espoir apres une desillusion. [Pneumology. Treatment of idiopathic pulmonary fibrosis: hopes and disappointment]

Details

Serval ID
serval:BIB_2A33A30C80B4
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Pneumologie. Traitement de la fibrose pulmonaire idiopathique: un espoir apres une desillusion. [Pneumology. Treatment of idiopathic pulmonary fibrosis: hopes and disappointment]
Journal
Revue Médicale Suisse
Author(s)
Rochat  T., Leuenberger  P.
ISSN
1660-9379 (Print)
Publication state
Published
Issued date
01/2005
Volume
1
Number
2
Pages
153-4, 156-8
Notes
English Abstract
Journal Article
Review --- Old month value: Jan 12
Abstract
Idiopathic pulmonary fibrosis (IPF) is now recognized as a separate nosological entity. Despite the progresses in understanding the basic mechanisms of the disease, its prognosis remains poor. The classical treatment combines prednisone with a cytotoxic agent. Interferon gamma has the in vitro capacity of inhibiting fibroblasts proliferation. A pilot study showed positive results, but a more recent randomized double blind trial was unable to demonstrate a clear benefit to the patients. On the other hand there are many evidences for an oxydant-antioxydant imbalance in the pathogenesis of IPF. In a human controlled study N-acetylcysteine (NAC) at high doses (1800 mg per day orally) improved the pulmonary function tests when given on top of a combined therapy with prednisone and azathioprine.
Keywords
Humans Interferon Type II/therapeutic use Pulmonary Fibrosis/*therapy Randomized Controlled Trials
Pubmed
Create date
25/01/2008 9:49
Last modification date
20/08/2019 13:09
Usage data